Nektar Therapeutics Stock
-
Your prediction
Nektar Therapeutics Stock
Nektar is a clinical-stage biopharmaceutical company focused on developing treatments for cancer, autoimmune diseases, and chronic pain. The company's pipeline includes product candidates based on its proprietary drug delivery technology, which improves the delivery and effectiveness of drugs in the body. Some of its most advanced candidates include NKTR-214, a cancer immunotherapy, and NKTR-181, a non-opioid pain medication. Nektar is listed on the NASDAQ exchange under the ticker symbol NKTR.
Pros and Cons of Nektar Therapeutics in the next few years
Pros
Cons
Performance of Nektar Therapeutics vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Nektar Therapeutics | - | - | - | - | - | - | - |
| Ironwood Pharmaceuticals | 2.690% | 34.507% | 45.802% | -75.259% | -77.262% | -91.861% | -89.148% |
| Novocure Ltd | 0.240% | 6.606% | -24.764% | -36.168% | -64.423% | -86.868% | -84.130% |
| Iovance Biotherapeutics Inc. | 4.280% | 16.329% | 16.329% | -77.862% | -67.608% | -82.575% | -90.914% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.In general, Nektar Therapeutics (NKTR) from the Biotechnology & Medical Research industry presents an interesting financial profile. The company seems to have struggled with net income over the last few years but maintains a consistent cash position and sizeable investments. Below is a comprehensive analysis of the company's financials, including notable pros and cons to consider.
Solid Cash Position: NKTR has maintained a reasonably strong cash position throughout the years, with an end-period cash balance of $102.6 million in 2020, $25.2 million in 2021, and $88.2 million in 2022. As of Q1 2023, the cash balance stands at $76.9 million, indicating that the company has been able to consistently generate and preserve cash.
Growing Total Assets: The company registered an increase in total assets from $1.54 billion in 2020 to $1.12 billion in 2021, although there was then a decrease to $710.6 million in 2022. Despite the recent decline, the overall trend in asset growth signifies that the business is expanding.
Comments
News
Why Nektar Therapeutics Stock Popped 6% on Friday
Biotech Nektar Therapeutics (NASDAQ: NKTR) unveiled its latest quarterly earnings after the stock market's close on Thursday, and the investor reaction was strong the following day. Happily for
Nektar (NKTR) Q2 Revenue Falls 52%
Nektar Therapeutics (NASDAQ:NKTR), a clinical-stage biopharmaceutical company focusing on immunology and oncology drug development, reported its latest financial results on August 7, 2025, for the
3 Bullish Biotech Stocks With Explosive Growth Trends
Investing in biotechnology stocks is similar to the drug development process itself. That is, investors frequently experience long periods of nothing much happening, interrupted by periods of
